CD3D

Across TCGA pan-cancer cohorts, CD3D mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD3D data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD3D mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CD3D expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CD3D mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.829	0.271	.003	27	view →
LUAD	DFS	Tertile	All	0.806	0.427	.001	25	view →
CCRCC	OS	Median	II,III,IV	1.000	0.505	.001	14	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD3D–PDAC (OS)

Open the PDAC breakdown →